MyoKardia participates in a conference call with Cantor Fitzgerald » 16:4106/0106/01/20
Conference call with…
Conference call with management will be held on June 3 at 1:30 pm hosted by Cantor Fitzgerald.
|Over a week ago|
MyoKardia price target raised to $188 from $95 at Cantor Fitzgerald » 07:1705/2005/20/20
Cantor Fitzgerald analyst…
Cantor Fitzgerald analyst Alethia Young raised the firm's price target on MyoKardia to $188 from $95 and keeps an Overweight rating on the shares following last week's positive pivotal EXPLORER readout last week and updating her model to reflect success in the obstructive HCM population, with estimated peak sales of ~$3B. Young says the data were more robust than she expected and left little room for doubt on either efficacy or safety for mavacamten. She would remain bullish into filing and approval over the next 12 months.
MyoKardia price target raised to $148 from $90 at BMO Capital » 08:1805/1405/14/20
BMO Capital analyst…
BMO Capital analyst George Farmer raised the firm's price target on MyoKardia to $148 from $90 and keeps an Outperform rating on the shares. The company's recent Phase 3 EXPLORER trial data evaluating mavacamtenfor treatment of obstructive hypertrophic cardiomyopaty was "highly meaningful" and supportive of a "robust treatment effect", while safety factors appear to be a "non-issue", the analyst tells investors in a research note. Farmer contends that regulatory approvals for mavacamtenfor should be "relatively straightforward".
MyoKardia 5.25M share Spot Secondary priced at $105 » 06:0405/1305/13/20
BofA, JPMorgan and Credit…
BofA, JPMorgan and Credit Suisse acted as joint book running managers for the offering.
MyoKardia 5.25M share spot secondary prices at $105/shr, Bloomberg says 20:1205/1205/12/20
MyoKardia takeout value in $160 to $190 per share range, says Citi » 06:2205/1205/12/20
Citi analyst Mohit Bansal…
Citi analyst Mohit Bansal raised the firm's price target on MyoKardia to $125 from $87 and keeps a Buy rating on the shares. The company's "home-run" EXPLORER trial data is just the beginning as its "Divide and Conquer" approach for cardiovascular indications could provide more such outcomes, Bansal tells investors in a research note. The analyst sees MyoKardia's takeout value in the $160-$190 per share range. The stock closed Monday up $35.81 to $96.90.
Fly Intel: Wall Street's top stories for Monday » 17:2305/1105/11/20
TSLA, AMC, AMZN, QDEL, UAA, UA, MYOK, CAH, AN, SSRM, ALIAF, MOS
The S&P started the week…
MyoKardia files to sell $450M in common stock » 16:0305/1105/11/20
BofA Securities, J.P.…
BofA Securities, J.P. Morgan and Credit Suisse are acting as joint bookrunning managers for the proposed offering. Cantor and Wells Fargo Securities are also acting as bookrunning managers in the offering. BMO Capital Markets and Wedbush PacGrow are acting as co-lead managers.
MyoKardia price target raised to $145 from $104 at Cowen » 14:4105/1105/11/20
Cowen analyst Ritu Baral…
Cowen analyst Ritu Baral raised the firm's price target on MyoKardia to $145 from $104 and keeps an Outperform rating on the shares after the company announced top-line results from the EXPLORER-HCM study of mavacamten in obstructive hypertrophic cardiomyopathy.
MyoKardia price target raised to $127 from $90 at Wedbush » 13:3205/1105/11/20
MYOK, NVS, BAYRY, AMGN
Wedbush analyst David…
Wedbush analyst David Nierengarten raised the firm's price target on MyoKardia (MYOK) to $127 from $90 and keeps an Outperform rating on the shares following what he called "impressive" topline data from a Phase 3 trial of mavacamten in patients with symptomatic obstructive hypertrophic cardiomyopathy, or oHCM. The EXPLORER trial hit all of its primary and secondary endpoints with high statistical significance and safety was better than expected, Nierengarten said. He "fully expects" approval in Q4 of 2021, sees mavacamten climbing to worldwide sales across indications of greater than $4B by 2027, and views MyoKardia as an attractive M&A candidate for potential buyers that could include Novartis (NVS), Bayer (BAYRY), Amgen (AMGN) and others, Nierengarten tells investors.